Key statistics
As of last trade Spyre Therapeutics Inc (3920:STU) traded at 31.00, -2.52% below its 52-week high of 31.80, set on Feb 13, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 28.80 |
|---|---|
| High | 31.80 |
| Low | 28.80 |
| Bid | 30.80 |
| Offer | 31.00 |
| Previous close | 29.00 |
| Average volume | 85.71 |
|---|---|
| Shares outstanding | 77.59m |
| Free float | 71.10m |
| P/E (TTM) | -- |
| Market cap | 2.84bn USD |
| EPS (TTM) | -2.55 USD |
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Announcements
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
- Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
- Spyre Therapeutics to Participate in Upcoming November Investor Conferences
- Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
- Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
- Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
- Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
- Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
More ▼
